ArticleBMJ open2022

Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).

Cornelia Bala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.